The monoclonal antibody cetuximab, while not as effective ... and co-leader of the UC San Diego Moores Cancer Center Head/Neck Disease Team. In a clinical trial, Mell and cancer researchers ...

As the researchers noted, head-and-neck cancers are relatively common ... but it turned out to be potentially worse than the ...

Optimal treatment for patients with locally advanced head and neck squamous cell carcinoma (HNSCC) unfit for cisplatin ...

A new trial finds that cetuximab outperforms durvalumab as a second-line treatment in patients who cannot tolerate cisplatin.

As the researchers noted, head-and-neck cancers are relatively ... The trial also found that cetuximab was effective regardless of whether or not a cancer was caused by HPV infection.

In a clinical trial, Mell and cancer researchers from two dozen other institutions compared the effectiveness of durvalumab and cetuximab — in combination with radiation therapy — in 186 patients with ...

For patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC) with a contraindication for cis ...